[Acute lymphoblastic leukemia of T progenitors: from biology to clinics]

Med Clin (Barc). 2015 Mar 9;144(5):223-9. doi: 10.1016/j.medcli.2014.01.029. Epub 2014 Mar 22.
[Article in Spanish]

Abstract

Acute lymphoblastic leukemia (ALL) is the most common cancer in children and the main cause of morbidity among childhood blood disorders. There are 2 subtypes according to the affected lymphoid progenitor: B-ALL and T-ALL. The T-ALL is the less common and, although historically was associated with poor prognosis in both adults and children, at present, treatment outcomes do not differ significantly between the 2 types of ALL. The T-ALL subtype is the most complex and heterogeneous at the genetic level and currently the one with less new therapeutic alternatives available. This trend is changing thanks to the remarkable progress upon understanding its biology. This review summarizes the most recent and important biological findings in T-ALL and their possible therapeutic implications.

Keywords: Acute T-cell lymphoblastic leukemia; Biology; Biología; Leucemia aguda linfoblástica T; Marcadores moleculares; Molecular markers; Tratamiento; Treatment.

Publication types

  • English Abstract
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Antineoplastic Agents / therapeutic use
  • Genetic Markers
  • Genetic Predisposition to Disease
  • Humans
  • Precursor T-Cell Lymphoblastic Leukemia-Lymphoma* / diagnosis
  • Precursor T-Cell Lymphoblastic Leukemia-Lymphoma* / drug therapy
  • Precursor T-Cell Lymphoblastic Leukemia-Lymphoma* / genetics
  • Prognosis

Substances

  • Antineoplastic Agents
  • Genetic Markers